Found 286 articles for: "biologics"
JAK Inhibitors in Psoriasis: A Promising New Treatment Modality
August 2012 | Volume 11 | Issue 8 | Original Article | 913 | Copyright © August 2012
Background: Inflammatory cytokines play a crucial role in the pathophysiology of psoriasis. New therapies are targeting Janus kinases (JAKs), enzymes involved with transduction of cytokine rece...
Read MoreMessage from the Guest Editor
August 2012 | Volume 11 | Issue 8 | Editorials | 906 | Copyright © August 2012
When and How to Use Biologics
May 2012 | Volume 11 | Issue 5 | Department | 4 | Copyright © May 2012
This supplement to the Journal of Drugs in Dermatology help address various components of psoriasis and comorbidities, as well as hidradenitis suppurativa and biologic treatments. Dr. Kircik and Onuma...
Read MoreCLINICAL TRIAL REVIEW
May 2012 | Volume 11 | Issue 5 | Features | 671 | Copyright © May 2012
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select...
Read MoreTreatment of Generalized Vitiligo With Anti-TNF-α Agents
April 2012 | Volume 11 | Issue 4 | Case Reports | 534 | Copyright © April 2012
Background: Although the exact pathogenesis of vitiligo is not fully understood, it appears to be an autoimmune disease. It is hypothesized that tumor necrosis factor alpha (TNF-α) plays ...
Read MorePsoriasis in African-Americans: A Caregivers' Survey
April 2012 | Volume 11 | Issue 4 | Original Article | 478 | Copyright © April 2012
Background: Psoriasis is a common skin disease in Caucasians but less common in African-Americans.
Aims: Our aim is to evaluate caregiver opinions regarding the clinical presentat...
Read MoreAdrenergic Urticaria and Rheumatoid Arthritis in a Patient With Melanoma: An Intricate Medical Management
March 2012 | Volume 11 | Issue 3 | Case Reports | 409 | Copyright © March 2012
A 45-year-old woman with marital and working troubles, a personal history positive for malignant melanoma, and a family history of vitiligo presented with adrenergic urticaria (AU), which at first res...
Read MoreA Phase 2, Open-Label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Allergic Contact or Atopic Dermatitis
March 2012 | Volume 11 | Issue 3 | Original Article | 341 | Copyright © March 2012
Objective: Evaluate the efficacy and safety of apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, in subjects with recalcitrant moderate to severe atopic dermatitis (AD) or allergic cont...
Read MoreAn Update on the Long-Term Safety Experience of Ustekinumab: Results From the Psoriasis Clinical Development Program With up to Four Years of Follow-Up
March 2012 | Volume 11 | Issue 3 | Original Article | 300 | Copyright © March 2012
Background: The efficacy and safety profile of ustekinumab with up to three years of exposure suggested a favorable benefit-risk profile in patients with moderate to severe psoriasis.
Read More Novel Therapies for the Treatment of Metastatic Melanoma
February 2012 | Volume 11 | Issue 2 | Features | 271 | Copyright © February 2012
Ustekinumab: A Review in the Treatment of Plaque Psoriasis and Psoriatic Arthritis
February 2012 | Volume 11 | Issue 2 | Original Article | 160 | Copyright © February 2012
Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably affects the skin, nails, and joints. In September 2009, ustekinumab (Stelara®), a monoclonal antibody that ta...
Read MoreA Review of the Chemopreventative Effects of Oral Retinoids for Internal Neoplasms
November 2011 | Volume 10 | Issue 11 | Original Article | 1292 | Copyright © November 2011
With the recent data showing that psoriasis patients are at higher risk for systemic malignancies, there is a growing awareness for the need to minimize cancer risks in psoriasis patients. Retinoids a...
Read MorePIPELINE PREVIEWS
October 2011 | Volume 10 | Issue 10 | Features | 1215 | Copyright © October 2011
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from the...
Read MorePipeline Previews
August 2011 | Volume 10 | Issue 8 | Features | 938 | Copyright © August 2011
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This de...
Read MoreAcitretin for the Treatment of Psoriasis: An Assessment of National Trends
August 2011 | Volume 10 | Issue 8 | Original Article | 873 | Copyright © August 2011
Background: Combination therapy is a common and appropriate treatment strategy for moderate-to-severe psoriasis, as it provides for enhanced ...
Read MoreIncreased Prevalence of Psychiatric Disorders and Health Care-Associated Costs Among Patients With Moderate-to-Severe Psoriasis
August 2011 | Volume 10 | Issue 8 | Original Article | 843 | Copyright © August 2011
Objective: To characterize the prevalence of psychiatric disorders in patients with moderate-to-severe psoriasis and compare health care costs between patients with and without psychiatric como...
Read MoreInfliximab Treatment for Psoriasis in 120 Patients on Therapy for a Minimum of One Year: A Review
May 2011 | Volume 10 | Issue 5 | Original Article | 539 | Copyright © May 2011
Infliximab is a chimeric monoclonal antibody, which acts by binding to both the soluble and membrane-bound tumor necrosis factor-a. In clinical prac...
Read MoreAn Open-Label, Prospective Cohort Pilot Study to Evaluate the Efficacy and Safety of Etanercept in the Treatment of Moderate to Severe Plaque Psoriasis in Patients Who Have Not Had an Adequate Response to Adalimumab
April 2011 | Volume 10 | Issue 4 | Original Article | 396 | Copyright © April 2011
Background: The past several years have seen the approval of five different biologic agents for the treatment of moderate to severe plaque p...
Read MoreAdalimumab Plus Narrowband Ultraviolet B Light Phototherapy for the Treatment of Moderate to Severe Psoriasis
April 2011 | Volume 10 | Issue 4 | Original Article | 366 | Copyright © April 2011
Background: Combining systemic agents with phototherapy is becoming a standard of care for patients with moderate to severe psoriasis. The c...
Read MorePipeline Previews
March 2011 | Volume 10 | Issue 3 | Features | 324 | Copyright © March 2011
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from the...
Read More